Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape

Author:

Mast Fred D1ORCID,Fridy Peter C2ORCID,Ketaren Natalia E2ORCID,Wang Junjie3,Jacobs Erica Y34ORCID,Olivier Jean Paul1ORCID,Sanyal Tanmoy5ORCID,Molloy Kelly R3,Schmidt Fabian6,Rutkowska Magdalena6,Weisblum Yiska6ORCID,Rich Lucille M7,Vanderwall Elizabeth R7,Dambrauskas Nicholas1,Vigdorovich Vladimir1ORCID,Keegan Sarah8,Jiler Jacob B2ORCID,Stein Milana E2,Olinares Paul Dominic B3ORCID,Herlands Louis9,Hatziioannou Theodora6,Sather D Noah110ORCID,Debley Jason S71011,Fenyö David8ORCID,Sali Andrej5ORCID,Bieniasz Paul D612ORCID,Aitchison John D11013ORCID,Chait Brian T3ORCID,Rout Michael P2ORCID

Affiliation:

1. Center for Global Infectious Disease Research, Seattle Children's Research Institute

2. Laboratory of Cellular and Structural Biology, The Rockefeller University

3. Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University

4. Department of Chemistry, St. John’s University

5. Department of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, University of California, San Francisco

6. Laboratory of Retrovirology, The Rockefeller University

7. Center for Immunity and Immunotherapies, Seattle Children’s Research Institute

8. Institute for Systems Genetics and Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine

9. AbOde Therapeutics Inc

10. Department of Pediatrics, University of Washington

11. Division of Pulmonary and Sleep Medicine, Seattle Children’s Hospital

12. Howard Hughes Medical Institute, The Rockefeller University

13. Department of Biochemistry, University of Washington

Abstract

The emergence of SARS-CoV-2 variants threatens current vaccines and therapeutic antibodies and urgently demands powerful new therapeutics that can resist viral escape. We therefore generated a large nanobody repertoire to saturate the distinct and highly conserved available epitope space of SARS-CoV-2 spike, including the S1 receptor binding domain, N-terminal domain, and the S2 subunit, to identify new nanobody binding sites that may reflect novel mechanisms of viral neutralization. Structural mapping and functional assays show that indeed these highly stable monovalent nanobodies potently inhibit SARS-CoV-2 infection, display numerous neutralization mechanisms, are effective against emerging variants of concern, and are resistant to mutational escape. Rational combinations of these nanobodies that bind to distinct sites within and between spike subunits exhibit extraordinary synergy and suggest multiple tailored therapeutic and prophylactic strategies.

Funder

Mathers Foundation

Robertson Foundation

Jain Foundation

National Institutes of Health

Publisher

eLife Sciences Publications, Ltd

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3